THOR-707, a Novel Non Alpha IL-2, in Patients with Advanced/ Metastatic Solid Tumors

Time: 4:05 pm
day: Day Two


  • Hypothesis: why non alpha
    • Features: how THOR-707 spares the alpha receptor while binding to the
    beta-gamma receptor
    • Data: preliminary results from the ongoing Phase 1-2 clinical trial in
    patients with solid tumors